Photographs are for representational functions solely. File | Picture credit score: Getty Photographs/iStockphoto
The Central Medicine Customary Management Group (CDSCO) has issued an advisory to drug producers, importers and advertising license holders to make sure strict compliance with the provisions of the Medicine and Cosmetics Act, 1940 and Rules, 1945 within the promotion and advertising of prescribed drugs, notably GLP-1 receptor agonists and comparable medication indicated for weight problems and metabolic problems.
The advisory highlights considerations relating to sure promotional actions which will not directly promote prescription-only medicines to the general public, equivalent to illness consciousness campaigns and digital aids. CDSCO has clarified that such medicines should solely be prescribed by registered physicians in accordance with the authorized indications and the situations of the advertising authorization.
The regulator reiterated that direct or oblique promoting of prescribed drugs to the general public is strictly prohibited, together with promotional actions in print, digital, digital or social media platforms.
Actions that exaggerate the effectiveness of therapies, assure weight reduction advantages, or undermine the significance of way of life modifications equivalent to food regimen and bodily exercise are handled as deceptive promoting.
CDSCO suggested all related stakeholders to strictly adhere to regulatory and moral advertising requirements.
Firms are additionally directed to submit complete threat administration plans to make sure enough prescribing data, preserve client grievance mechanisms and guarantee ongoing security monitoring.
The suggestions emphasize that weight problems is a persistent metabolic illness that requires complete administration, together with way of life interventions, and that drug therapies shouldn’t be designed to undermine broader public well being efforts.
